1. Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis
- Author
-
Leggett C, James M. Hill, Thompson Bl, Louis P. Gangarosa, and Rissing Jp
- Subjects
Adult ,Male ,medicine.medical_treatment ,Acyclovir ,Pharmacology ,Virus ,chemistry.chemical_compound ,Recurrence ,medicine ,Humans ,Immunology and Allergy ,Aciclovir ,Viral shedding ,skin and connective tissue diseases ,Vidarabine ,Herpes Labialis ,Chemotherapy ,Arabinonucleotides ,Iontophoresis ,business.industry ,Virology ,Infectious Diseases ,chemistry ,Vidarabine phosphate ,Female ,business ,Vidarabine Phosphate ,medicine.drug - Abstract
The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P less than .05). Ara-AMP significantly decreased the duration of shedding of virus (P less than .05) and time to dry crust (P less than .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.
- Published
- 1986